A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT00852358

Condition

MPS 1, Mucopolysaccharidosis I, Hurler-Scheie Syndrome, Cognitive Decline, Scheie Syndrome, Lysosomal Storage Disease

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This is a 24-month study of the use of laronidase administered into the spinal fluid to treat cognitive decline in mucopolysaccharidosis I (MPS I). MPS I is a rare genetic condition due to deficiency of the enzyme alpha-l-iduronidase. Laronidase is the manufactured form of the enzyme alpha-l-iduronidase.

MPS I is a heterogeneous disease with several clinical phenotypes ranging from the most severe, Hurler syndrome, to the attenuated forms, Hurler-Scheie and Scheie. Although patients with milder forms of MPS I may not have grossly observable problems with cognition, these patients do have learning difficulties that are apparent in school and with neuropsychological testing. The goal of this study is to evaluate whether intrathecal recombinant human alpha-l-iduronidase (rhIDU) injections can stabilize or improve cognitive decline in individuals with MPS I.

Eligibility Criteria

Birth Sex

All

Age

From 6 Years

Healthy Volunteers

No

Drug/Treatment:

laronidase

Phase:

Na

Study Type:

Interventional

Number of Participants:

9

Study Started:

2009-06

Study Updated:

2016-01-26

Trial Locations

  • Children's Hospital & Research Center Oakland

    Oakland, California, United States

  • Los Angeles Biomedical Institute at Harbor-UCLA

    Torrance, California, United States

  • University of Minnesota

    Minneapolis, Minnesota, United States

Inclusion Criteria

  • The presence of MPS I disease as documented by low α-L-iduronidase activity
  • Age six years or older.
  • The presence of acquired cognitive deficits as demonstrated by:

1. A score of one standard deviation below mean on IQ testing or in one domain of neuropsychological function (language, memory, or non-verbal ability), OR
2. Documented historical evidence of a decline of greater than one standard deviation on sequential testing, OR
3. A score between 0.75 and 1 standard deviation below the mean, AND the cognitive deficit affects daily performance.

  • The decline in function is not explainable by other neurological or psychiatric factors.
  • Subject and/or guardian willing and able to provide written informed consent.
  • Negative urine pregnancy test at screening (non-sterile females of child-bearing potential only)
  • Currently using two acceptable methods of birth control as determined by the investigator and willing to continue to use acceptable birth control during their participation in the study (non-sterile females of child-bearing potential who are sexually active only)
  • Willing and able to comply with study procedures. For example, the subjects must be able to complete written and computer-based testing. The subjects must be able to lie still in the MRI scanner for at least 40 minutes without sedation.

Exclusion Criteria

  • The subject has undergone hematopoietic stem cell transplantation
  • Recent initiation of intravenous Aldurazyme® therapy with less than 6 months of therapy. Subjects who have been receiving Aldurazyme® therapy for more than 6 months, and those who have never received Aldurazyme® therapy, will be allowed to enroll
  • Pregnant or lactating, or considering pregnancy
  • Receipt of an investigational drug or procedure within 30 days of enrollment
  • A condition, medical or other, that prevents participation in the study, including severe auditory or visual impairment, significant lumbar pathology, lumbar catheter, or recent major surgery within 6 weeks that would preclude their ability to participate.
  • Infusion reactions to intravenous Aldurazyme® therapy that require ongoing medical intervention, special prophylaxis or altered rate or dose of enzyme administration
  • The subject has a programmable VP shunt that is incompatible with the 3 Tesla MRI magnet and is unable or unwilling to undergo shunt revision to a MRI compatible device.
  • The subject has another contraindication for MRI, such as nonremovable metal in the body.
  • The subject has severely impaired spinal CSF flow, demonstrated by failure of appearance of 99mTechnetium-DTPA in the basal cisterns by 4 hours after intra-lumbar administration

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our clinical trials.

By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.

*required fields

"*" indicates required fields

This field is hidden when viewing the form
This field is hidden when viewing the form